First-in-Human Ultrasound Molecular Imaging With a VEGFR2-Specific Ultrasound Molecular Contrast Agent (BR55) in Prostate Cancer
- 1 July 2017
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Investigative Radiology
- Vol. 52 (7), 419-427
- https://doi.org/10.1097/rli.0000000000000362
Abstract
Objective BR55, a vascular endothelial growth factor receptor 2 (VEGFR2)–specific ultrasound molecular contrast agent (MCA), has shown promising results in multiple preclinical models regarding cancer imaging. In this first-in-human, phase 0, exploratory study, we investigated the feasibility and safety of the MCA for the detection of prostate cancer (PCa) in men using clinical standard technology. Materials and Methods Imaging with the MCA was performed in 24 patients with biopsy-proven PCa scheduled for radical prostatectomy using a clinical ultrasound scanner at low acoustic power. Safety monitoring was done by physical examination, blood pressure and heart rate measurements, electrocardiogram, and blood sampling. As first-in-human study, MCA dosing and imaging protocol were necessarily fine-tuned along the enrollment to improve visualization. Imaging data were correlated with radical prostatectomy histopathology to analyze the detection rate of ultrasound molecular imaging with the MCA. Results Imaging with MCA doses of 0.03 and 0.05 mL/kg was adequate to obtain contrast enhancement images up to 30 minutes after administration. No serious adverse events or clinically meaningful changes in safety monitoring data were identified during or after administration. BR55 dosing and imaging were fine-tuned in the first 12 patients leading to 12 subsequent patients with an improved MCA dosing and imaging protocol. Twenty-three patients underwent radical prostatectomy. A total of 52 lesions were determined to be malignant by histopathology with 26 (50%) of them seen during BR55 imaging. In the 11 patients that were scanned with the improved protocol and underwent radical prostatectomy, a total of 28 malignant lesions were determined: 19 (68%) were seen during BR55 ultrasound molecular imaging, whereas 9 (32%) were not identified. Conclusions Ultrasound molecular imaging with BR55 is feasible with clinical standard technology and demonstrated a good safety profile. Detectable levels of the MCA can be reached in patients with PCa opening the way for further clinical trials.Keywords
This publication has 31 references indexed in Scilit:
- Ultrasound-contrast-agent dispersion and velocity imaging for prostate cancer localizationMedical Image Analysis, 2017
- Dynamic Contrast-enhanced MR Imaging Curve-type Analysis: Is It Helpful in the Differentiation of Prostate Cancer from Healthy Peripheral Zone?Radiology, 2015
- Magnetic Resonance Dispersion Imaging for Localization of Angiogenesis and Cancer GrowthInvestigative Radiology, 2014
- Innovations in diagnostic imaging of localized prostate cancerWorld Journal of Urology, 2013
- Optimization of Initial Prostate Biopsy in Clinical Practice: Sampling, Labeling and Specimen ProcessingJournal of Urology, 2013
- Image-Guided Prostate Biopsy Using Magnetic Resonance Imaging–Derived Targets: A Systematic ReviewEuropean Urology, 2013
- Angiogenesis in prostate cancer: onset, progression and imagingBJU International, 2012
- Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesisClinical Radiology, 2008
- Angiogenesis in cancer and other diseasesNature, 2000
- Induction of angiogenesis during the transition from hyperplasia to neoplasiaNature, 1989